Index

45 and Up Study, 119

absolute risk

absolute risk increase (ARI), 150, 466
absolute risk reduction (ARR), 150–1, 155, 466
accuracy, 76, 80, 82–3, 86, 94, 125, 129, 201–2, 300, 386–7, 391, 393–5 see also error, systematic
active surveillance, 320, 327
aetiologic fraction see attributable fraction; population attributable fraction
age-specific rates, 51, 57, 451, 455, 457
AIDS see HIV/AIDS
American Institute of Cancer Research, 307
analytic studies, 23, 105, 129, 188, 196, 214, 249
ascertainment bias, 192
association
versus causation, 275–6
measures of, 163
asthma and BMI (body mass index), 255–6
attack rate, 4, 32, 42, 265 see also incidence proportion
secondary, 339
attributable burden, 371
attributable fraction (AF)
calculation of, 149
in case–control studies, 139
in disease prevention, 154
interpretation of, 150–1
in population see population attributable fraction (PAR)
worked example, 150, 164
attributable proportion see attributable fraction
attributable risk (AR), 147–9, 152, 154, 160
see also rate difference; risk difference
calculation of
in case–control studies, 160–1
in clinical epidemiology, 150–1
in population see population attributable risk (PAR)
interpretation of, 153–4
versus relative risk, 155–6
worked example, 155
attributable risk per cent see attributable fraction
avoidable burden, 372
Avon Longitudinal Study of Parents and Children (ALSPAC) (UK), 117
background risk or rate, 147
BCG vaccination see tuberculosis
beta-carotene, trials for anti-cancer effects, 419
bias
ascertainment or detection, 192
healthy worker effect, 193
interviewer or observer, 125, 209–10
lead-time, 402–6
length-time, 402, 407
loss to follow-up, 192
measurement see measurement error, misclassification
publication, 291
recall, 116, 125, 208–9
selection see selection bias
volunteer, 402
bicycle helmets and head injury, 161–2, 284
biological plausibility, as factor in evaluating causality, 283
birth defects and thalidomide, 122, 307
‘blinding’ in clinical trials, 110
BMI (body mass index) and asthma, 255–6
brain cancer and mobile phones, 301
breast cancer
control of, 259, 393
screening for, 309, 377, 388, 403–6
British Doctors’ Study, 16, 23–4, 117, 155, 281–2
burden of disease, 32, 145, 153, 309, 337, 370

483
Index

cancer see also specific types of cancer
and diet, 99
beta-carotene trials, 376, 419
dedicated websites, 87
epidemiology, 5
registries, 87, 198, 323
cardiovascular disease (CVD)
and high blood pressure, 364–5
definitions, 52
mortality rates, 20
proposed ‘Polypill’ prevention strategy, 376
risk factor profiles in Finland and China, 362
case-fatality ratio (CFR), 58–9, 71
case reports, 76–8
case series, 76–8
case–cohort studies, 120–1
case–control studies
advantages and disadvantages of, 121, 123
attributable risk in, 160–1
confounding in, 242, 418
control selection for, 194
design of, 122–3
hospital controls, 252
matching in, 232–3
measuring relative risk in, 157–8
misclassification in, 205, 208
nested case–control study, 120–1, 433
odds ratios for, 160
population attributable fraction in, 160
recall bias in, 125, 209, 212
selection bias in, 125, 196, 198
case–crossover study, 126
case-finding, versus screening, 385
case-reference (or case-referent) studies
see case–control studies
causation
causal reasoning, 279–80
component cause, 272
definitions of causes, 272
evaluation of, 283–5
models of, 338
necessary cause, 271
sufficient cause, 271
versus association, 275–6
Centers for Disease Control and Prevention (CDC) (USA), 346, 414
CER see control event rate
cervical cancer
and human papillomavirus (HPV) infection, 382, 425
screening programmes for, 383
CFR see case-fatality ratio
case-fatality ratio
chance (random sampling error), 170–1
assessment of effects of, 214
confidence intervals, 173–4
hypothesis testing, 171, 173
multiple testing, 180
power, 175–6
p-values, 174–5, 177
type I error, 172
type II error, 171, 175
CHD see coronary heart disease
case death rate, 61
childhood mortality and vitamin A, 109, 109
cholera epidemic, John Snow investigation of, 16, 275
cholesterol and ischaemic heart disease, 366
CI see confidence intervals
cigarette smoking see smoking
clinical epidemiology, 6
attributable risk in, 150–1
incidence proportion in, 46, 47
diagnostic studies, 129
number needed to treat (NNT), 151
predictive values in, 394–5
prognostic studies, 120
relative risk in, 145–6
clinical significance, 181, 260
case–control studies
clustering, 335–6
definitions of, 343
event rates, 335
investigation of, 343–4
Cochrane Collaboration database, 258–9
cohort studies, 99, 105, 116–20
45 and Up Study, 118
advantages and disadvantages of, 116
Avon Longitudinal Study of Parents and Children (ALSPAC) (UK), 117
British Doctors Study, 117
Index

485

case–cohort studies, 120–1
confounding in, 200, 210, 225
design of, 114
European Prospective Investigation into Cancer (EPIC), 433
Framingham Heart Study, 115
generalisability, 116
internal validity, 188
loss to follow-up, 189, 192
Million Women Study, 433
misclassification in, 116
nested case–control studies, 121
Nurses’ Health Study, 116–17, 188
prognostic studies, 120
record linkage, 118–19
retrospective or historical, 118
selection bias in, 188–9
communicable diseases see infectious diseases
community trials, 113 see also intervention studies
component cause, 271–4, 286
conditional logistic regression, 238
confidence intervals (CI), 173–4
and p-values, 174–5, 177–8
evaluating role of chance, 181
confidentiality, 100
confounding, 28, 217–45
and study size, 235
assessment of effects, 243
by indication, 230–1
common confounders, 223
conditions for confounding to occur, 225–8
control through data analysis, 235–43
case–cohort study, 120–1
control through study design, 230–5
criteria for a confounder, 221–3
versus effect modification, 236–7
effects of, 223–8
example of, 219–21
in a case–control study, 219, 227, 233
cohort study, 218, 225
in an ecological study, 99
matching, to control, 232–3
modelling, to control, 238
randomisation, to control, 230–1
residual, 240–3
restriction, to control, 231–2
Simpson’s paradox, 217, 223
stratification, to control, 235–8
congenital abnormalities and rubella, 38
consistency, as factor in evaluating causality, 281, 302
case–cohort studies, 120–1
control event rate (CER), 47, 146 see also incidence proportion
case–control studies, 114
control group see also case–control studies
hospital controls, 124–5
population controls, 124
coronary heart disease (CHD) see also cardiovascular disease, ischaemic heart disease and smoking, 182, 281
terminology, 52
registries (MONICA Programme), 88
correlation studies see ecological studies
Counterfactual, 107, 111, 272, 279–80
Cox proportional hazards regression,
238
Creutzfeldt-Jacob disease (CJD)
and blood transfusions, 252–3
critical point, in the disease process, 385
cross-level bias, 48, see also ecological fallacy
cross-sectional studies, 127–9
avoiding selection bias, 128
design of, 127
recall bias, 209
cross-over trial, 111–12
crude rates, 49, 51
cumulative incidence (CI) see incidence proportion
CVD see cardiovascular disease
DALY see disability-adjusted life year
data analysis
conditional logistic regression, 238
Cox proportional hazards modelling, 238
matched data, 233–4
multiple logistic regression, 238
multivariable modelling, 238
dead
death certificates, 80, 83, 86
establishing cause of, 49, 66, 80, 83
national registers, 81
rates see mortality rates
Declaration of Helsinki, 131
Demographic and Health Surveys (DHS), 93

density sampling, 159
depression, risk factors for, 257
descriptive epidemiology, 7, 13, 23, 41, 333
descriptive studies, 196
  - assessing results of, 263–4
    - by person, place and time, 19–20, 22
    - selection bias in, 188
detection bias, 192
diabetes (mellitus)
  - and BMI (body mass index), 282, 370
  - gestational, 33–4
  - mortality and ICD changes (USA), 85
diagnostic criteria, 33
diagnostic studies, 129, 390
diagnostic tests
  - accuracy and predictive values, 395
diet and cancer, 24
diethylstilboestrol (DES) exposure and
  - vaginal cancer risk, 176
difference measures see attributable risk;
  - rate difference; risk difference
differential error/misclassification
  - estimation of effects of, 197
    - sources, 197
directed acyclic graphs, 223, 229–30
direct standardisation, 52, 57, 147, 451
disability-free life expectancy, 64–5
disability-adjusted life years (DALY), 31, 68–70
disease
  - diagnostic criteria, 33
  - endemic and epidemic, 470
  - natural history of, 18
  - transmission, 13
Doll, Sir Richard, 16–17, 23–4
dose–response relationships, in evaluating
  - causality, 269, 282
ecological fallacy, 48, 99, 470
ecological studies, 62, 98–9, 103–4, 129–30, 134, 250, 409–10, 432, 468, 470
EER see experimental event rate
effect modification, 236–7, 470, 481
eligibility and exclusion criteria, 195
endemic disease, 336–8
epidemic (outbreak)
  - common conditions for occurrence/cessation, 41
curve, 15, 348–9
definition of, 8–11
examples of, 19
index case, 129
investigation of, 4
management of, 345–6
point-source, 348
prevention, 357
propagative (contagious), 349
epidemiology
  - analytic, 105, 419
  - boundaries of, 5
  - cancer, 5
  - clinical, 6, 46, 150–1
definitions of, 2
  - descriptive, 7, 13, 23, 41, 75, 105, 333, 426
  - environmental, 5
  - historical beginnings, 8–10
  - infectious diseases, 4, 336–8
  - injury, 5
  - lifecourse, 6, 106, 423
  - molecular, 6, 299
  - nutritional, 4, 24
  - occupational, 5
  - perinatal, 5
  - pharmacoepidemiology, 126
  - public health, 6, 23
  - scope of, 2
  - social, 4, 106
error, sources of see also selection bias, measurement error, misclassification
  - in subject selection see selection bias
  - in measurement see measurement error
  - random, 183, 201
  - systematic, 201–2
  - ethics, 130–1
  - Declaration of Helsinki, 131
  - Nuremberg Code, 131–3
European Prospective Investigation into
  - Cancer (EPIC), 116
excess rate/risk see rate/risk difference
  - exchangeability, 107, 109, 111, 112, 140, 188, 235, 241, 425
  - exclusion criteria, 195
expected years of life lost (EYLL), 65–6
experimental event rate (EER), 47, 146
  - see also incidence proportion
experimental studies see intervention studies
external validity of results, 188
Farr, William (1807–1883), 13, 275
follow-up studies see cohort studies
force of morbidity, 44, 471
forest plots, 294, 297
Framingham Heart Study, 115–16, 188
gastric cancer see stomach cancer
generalisability (external validity), 116, 128, 188, 248, 262–3
genetic versus environmental effects, 18
gestational diabetes, 33–4
global warming, and infection risks, 337
Goldberger, Joseph (1620–1674) and pellagra, 16
Graunt, John (1620–1674), 11–13
HALE see health-adjusted life expectancy
hazard ratio, 233, 238
head injury and bicycle helmets, 161–3, 284
health, definition of, 18
health data
ethical use of, 100
morbidity data, 77, 87
mortality data, 19, 49, 79, 86, 275, 377
privacy concerns, 119
sources of summary, 77
Health Insurance Plan (HIP), study of breast cancer screening, 404
health-adjusted life expectancy (HALE), 2, 31, 67, 471
health-adjusted life years
disability-adjusted life years (DALY), 31, 68, 70
quality-adjusted life years (QALY), 31, 66
Health and Demographic Surveillance Systems (HDSS), 82–3
health expectancy, measures of, 65, 471
health gaps, measures of, 65, 69, 471
healthy-worker effect, 192–3, 472
heart attack see myocardial infarction
heart disease see coronary heart disease; ischaemic heart disease; cardiovascular disease
Helicobacter pylori infection and stomach cancer, 97, 250, 285
hepatitis
A and C, 393
surveillance for hepatitis C, 39
heterogeneity, of study results, 237, 281, 294, 298, 300, 302, 304, 472
high blood pressure, and CVD, 364
high-risk strategy for disease prevention, 367, 370
Hill, Sir Austin Bradford, 278
Hippocrates of Cos, 11
historical cohort study, 118–19, 232, 479
HIV/AIDS
identification of, 34
prevalence and incidence rates, 34–6
screening of blood donors, example, 391–4
hospital records, for morbidity data, 86, 88
host see infectious diseases, host factors human papillomavirus (HPV) infection, and cervical cancer, 232, 425–6
Human Research Ethics Committee (HREC), 100, 130
Hume, David (Hume’s problem), 277
hypothesis testing
and p-values, 174–5
type I error, 171
confirmation and refutation, 277
power and type II error, 175–6
IHD see ischaemic heart disease
incidence see also incidence proportion; incidence rate
relationship with prevalence and duration, 39–40
standardised incidence ratio (SIR), 52, 56–7
incidence density see incidence rate
incidence proportion, 41–2 see also attack rate
calculation of, 43
target event rate (CER), 47
definition, 43
experimental event rate (EER), 47
from routine data, 54–5
measurement in epidemiological studies, 46
versus incidence rate, 44–5
incidence rate (IR), 46–8
age-specific, 50–1
incidence rate (IR) (cont.)
calculation of, 43–4
definition of, 43

crude, 49–50
from routine data, 48–9
measurement in epidemiological studies, 41–3, 46–8
incidence rate difference, 42
incidence rate ratio, 158, 233, 238
versus incidence proportion, 44–5

incubation period for disease, 317, 334, 340, 348, 351, 473

Indigenous Australians, mortality ratios, 19, 56
indirect standardisation, 57–8, 457, 473
infant mortality rate, 11, 61–3, 67
infection see also infectious agents;
infected control of, 340
definition of, 7
elimination of, 316
eradication of, 316
intensity of, 473

infectious agents
case–fatality ratio (CFR), 339
incubation period, 340
infectivity, 339
infestation, 339
intensity of infection, 339
latent period, 340
pathogenicity, 339
reservoirs, 339
secondary attack rate, 339
sources, 340
transmission of, 340–2
virulence, 339

infectious diseases
and environmental change, 342
causal models, 338–9
definition, 336
endemic, epidemic, pandemic, 335–6
epidemiology of, 335–8
factors affecting spread, 335
host factors, 340
infectivity, 339, 473, 479
infestation, 339, 473

influenza
H1N1 (‘swine flu’) outbreaks, 77, 325, 336, 384
H5N1 (avian influenza) outbreaks, 325, 337
information error see measurement error
injury epidemiology, 5
International Agency for Research on Cancer (IARC), 87, 94, 288, 306
interval cases, 473
intervention studies, 24, 108–9 see also randomised controlled trials
community trials, 113
field trial of polio vaccine, 108
International Studies of Infarct Survival (ISIS), 108
vitamin A and childhood mortality, 109
water fluoridation and dental health, 113

interviewer bias, 254

ischaemic heart disease see also cardiovascular disease, coronary heart disease
DALYs due to, 274
termology, 365
inverse association with wine consumption, 99
mortality rates, 50–3
serum cholesterol level and, 365
instrumental variables, 241–2, 424
International Studies of Infarct Survival (ISIS), 108

kidney disease, and phenacetin, 123
Kinsey, studies of sexual behaviour, 190

latent period of infection, 340
lead-time, 402
lead-time bias, in screening programmes, 403, 406
length-time bias, in screening programmes, 407
life expectancy, 63–4
disability-free life expectancy, 64–5
health-adjusted life expectancy (HALE), 67

© in this web service Cambridge University Press
www.cambridge.org
lifecourse epidemiology, 6, 106, 423
life-table, 11, 64
lifetime risk, from routine data, 55
Lind, James and scurvy, 108
logistic regression, 238
loss to follow-up, 192
sensitivity analysis for, 199–200
lung cancer
and smoking, 16, 55, 70, 95, 106, 141–2, 148, 218, 223
British Doctors Study, 16, 24, 41, 117, 155
control of, 118, 363
mortality rates, 7, 94, 155
mammography
debate concerning, 308
screening for breast cancer, 404
Mantel-Haenszel odds ratio, 464–5
mass strategy for disease prevention, 356, 368
matching, to control confounding, 232–3, 235
analysis of matched data, 234
frequency matching, 232–3
individual, 234
maternal mortality rate, 61
measles
infectivity and pathogenicity, 339
vaccination strategy, 337
measurement error, 203, 205 see also
misclassification
assessing effects, 212
control of, 210
effects, 202
overview of, 212
random error, 187, 201–2, 204, 212
sources of, 208
systematic error, 187, 201, 204–5, 212
measures of association, 57, 140, 159, 188, 351
attributable risk, 147–8, 150, 154
relative risk, 142, 157
worked example, 163
measures of disease
incidence rate, 38, 41, 43, 46, 147, 151
incidence rate versus incidence proportion, 44–5
prevalence, 34–6, 38, 41, 45, 189, 194, 369, 393
summary of, 71
use of percentages, 37
using routine data, 48
MEDLINE database, 290–1
Mendelian randomisation, 242
meta-analysis, 178, 294, 297, 299, 465
MI see myocardial infarction
migrant studies, 96
Millennium Development Goals, 60–1, 80, 87, 93, 427
Million Women Study (UK), 116
misclassification, 200, 203 see also
measurement error
differential, 205–7
assessment of effect of, 212–13
non-differential, 203–4, 206
molecular epidemiology, 299
morbidity, force of, 44
morbidity data, 86–9
mortality data, 49, 76–7, 79–83, 85–6
death certificates, 80, 86
establishing cause of death, 49, 66, 80, 83, 193
mortality rates, 21, 49
age-specific, 50
all-cause, 22, 55
cardiovascular disease (CVD), 20, 52, 404
child death rate, 61, 109
childbirth and early life, 11, 13, 60
crude mortality rates, 49–51, 53
Indigenous Australians, 19–20
infant mortality rate, 61–2, 67
lung cancer, 7, 17, 22, 94, 96, 155
maternal mortality rate, 61
neonatal mortality rate, 61
proportional mortality ratio (PMR), 58, 71
Russian men, 7, 68
standardised, 20, 49, 52, 54
stillbirth or fetal death rate, 61–2
stillbirth or fetal death ratio, 61–2
trends in USA, 55
multiple logistic regression see logistic regression
multivariable modelling, 238–40
myocardial infarction (MI), heart attack and sexual activity, 126
International Studies of Infarct Survival (ISIS), 108
mortality and streptokinase, 109
terminology, 59
n-of-1 randomised trials, 112
National Health and Nutrition Examination Surveys (NHANES), 91–2
narrative reviews, 289
natural history of disease, 18, 384, 386
necessary cause, 271–3, 317, 336, 382
negative predictive value (NPV), 390
neonatal mortality rate, 61, 67
nested case–control studies, 120–1, 433
NNT see number needed to treat
non-differential error/misclassification, 203–4, 214
estimation of effects of, 197
notifiable diseases, 87 see also surveillance number needed to treat (NNT), 151
Nuremberg Code, 131–2
Nurses’ Health Study (USA), 24, 116–17, 282
nutritional epidemiology, 5, 24
obesity
CVD and, 363
epidemic, 63
ovarian cancer and, 296–7
observation versus randomisation, 295
observer bias, 209
occupational epidemiology, 5
use of proportional mortality ratio (PMR), 57–8
odds ratio, 157–9, 179, 198, 204, 206, 213, 219–20, 236, 253
adjusted, 464
and relative risk, 157–60, 461
in a cross-sectional study, 41, 160
interpretation of, 158, 160
Mantel-Haenszel, 464–5
matched, 234
pooled, 220, 464–5
oesophageal cancer and smoking, 253
oral contraceptive use
and CHD, 226
and ovarian cancer risk, 122
and pulmonary embolism, 78
outbreak see epidemic
ovarian cancer
and obesity, 296–7
and oral contraceptive use, 122, 157, 361
and smoking, 195, 425
pandemic, 336
PAF see population attributable fraction
PAR see population attributable risk
passive health surveillance, 320
Pasteur, Louis, 342
pathogenicity, 339
pellagra, 16
person–years, 42–3, 141, 245
pharmacoepidemiology, 124, 126
phenacetin and kidney disease, 123
phenylketonuria (PKU), screening of new-borns, 387
Physicians’ Health Study, 108, 376
PMR see proportional (or proportionate) mortality ratio
Pneumocystis carinii pneumonia cluster
and discovery of HIV/AIDS, 78
point-source epidemic, 348
polio (poliomyelitis) surveillance for, 319
eradication and surveillance programmes, 319
field trial of polio vaccine, 108
infectivity, pathogenicity and virulence of virus, 339
‘Polypill’ for CVD prevention, 376
pooled analysis (re-analysis), 299
pooled odds ratios, 464–5
Popper, Karl and causal hypotheses, 277
population
study, 89, 90, 183, 194, 262
target, 89, 90, 170, 183, 188, 194, 296, 395
sampling, 90
population attributable fraction see population attributable fraction
population attributable risk see also attributable risk
calculation of, 152
interpretation of, 153, 155
worked example, 165
population attributable risk per cent see population attributable fraction
population strategy for disease prevention, 368
positive predictive value (PPV), 391, 412
post-test probability, 395 see also predictive values
potential impact fraction (PIF), 372
potential years of life lost (PYLL), 65–6, 69
power of a study, 176
precision see random error
predictive values (PPV and NPV), 391, 393, 412
pre-test probability, 395 see also prevalence
prevalence (P), 32, 35–6, 38–41, 45
calculation, 32, 35, 41
definition, 36
measurement in epidemiological studies, 41–2
period prevalence, 36
point prevalence, 36
pre-test probability, 395
relationship with incidence and duration, 39–40
ratios, 143, 145, 160
in cross-sectional studies, 127
prevalence surveys, 89
selection bias in, 188
prevention paradox, 378
prevention evaluation of prevention programmes, 18, 373
high-risk strategy, 366–7
mass or population strategy, 368
'middle-road' strategy, 369
paradox, 378
population attributable fraction (PAF) as a guide, 370–1
primary, 356–8
primordial, 358
secondary, 356, 378
suicide prevention programme (US Air Force), 374, 376
tertiary, 356
prognosis of disease, 18
prognostic studies, 120
propagative epidemics, 349
propensity scores, 231, 241
proportional (or proportionate) mortality ratio, 57–8 proportions, ratios and rates, 56
prospective studies see cohort studies
prostate cancer screening for, 305, 386
publication bias, 291
pulmonary embolism and oral contraceptive use, 78
p-values and statistical significance, 179, 182
and confidence intervals, 174, 177
PYLL see potential years of life lost
quality-adjusted life years (QALY), 31, 66–7
random error, 201–2, 205, 207
assessing effects on reported results, 203
in measurement, 201
in subject selection (sampling), 214 see also chance
randomisation to control confounding, 241
versus observation, 295
randomised controlled trials, 109, 111–14, 181, 235, 278, 290, 303, 433
blinding in, 110
confounding in, 230–1
crossover, 111–12
design of, 114
estimation of bias from loss to follow-up, 111
generalisability of, 263
loss to follow-up, 111, 192
n-of-1 trials, 112
parallel group, 111
selection bias in, 424
rare disease assumption, 160
rate difference, 141, 147–8, 156 see also attributable risk
rate ratio (RR), 141–2, 145, 235 see also relative risk
rates, ratios and proportions, 56
RCTs see randomised controlled trials
reading reports, 248–66
assessing results of descriptive studies, 263–4
assessing effects of chance, 259
assessing the study design, 250–1
checking for confounding, 257–8
checking for measurement bias, 253–4
Index

492

ing reading reports (cont.)
checking for selection bias, 251
external validity (generalisability) of
results, 262–3
identifying the research question, 250
internal validity of results, 260
writing reports, 264
recall bias, 116, 205, 208–9, 256
record linkage, 118–19
for surveillance, 263
relative risk (RR), 4, 20, 28, 142–3, 145, 157,
179 see also odds ratio; rate ratio; risk
ratio
in case–control studies, 156–7
in clinical epidemiology, 145–6
relative risk increase (RRI), 143, 146
relative risk reduction (RRR), 146
worked example, 164–5
versus attributable risk, 155–6
relative survival rate, 59
research designs see study designs
reservoirs of infection, 339–40
response rates, and selection bias, 190
restriction, to control confounding, 231
retrospective cohort study see cohort study
reverse causality, 24, 107, 116, 128
reviews of literature
narrative, 289
systematic, 289 see also systematic
reviews
risk difference, 149 see also attributable risk
risk ratio (RR), 143–5 see also relative risk
routine data
finding, 77–81
use in descriptive studies, 93–7
use to measure disease occurrence,
48–55
RR, RRI, RRR see relative risk
rubella and congenital abnormalities, 38
sampling error (random), 170–1 see also
chance and sample size (power)
screening, 381–414 see also screening
programme, screening test
aims of, 383
critical point, 385
definition of, 382
for bowel cancer, 388, 408
for breast cancer, 309, 388, 403, 406, 408
for cervical cancer, 383, 388, 407, 425
for phenylketonuria, 387
for prostate cancer, 305, 386, 411
relationship to the disease process, 384–5
versus case-finding, 385
screening programme
evaluation of, 401–3
lead-time bias, 403, 406
length-time bias, 407
negative consequences of, 410–11
requirements of the programme, 385–91,
393–4
requirements of the test, 385
sources of bias in evaluation of, 402
study designs to evaluate, 407–11
suitability of the disease, 386
volunteer bias, 402–3
screening test, 387
false positive and negative result, 389
negative predictive value (NPV), 390–1
positive predictive value (PPV), 390–1
requirements of, 386
sensitivity of, 388–90
specificity of, 388–90
trade-off between sensitivity and
specificity, 396–8
ture positive and negative result, 389
secondary attack rate, 339
secondary prevention, 356, 378
selection bias (systematic sampling error),
90, 124, 128, 170, 167–9, 196, 198, 251–2
assessing effects of, 196, 198, 212–13
control of, 194
effects of low response rates, 190
healthy worker effect, 192–3
in case–control studies, 195
in cohort studies, 189
in clinical trials, 214
in descriptive studies, 188
in evaluation of screening programmes,
401
loss to follow-up, 192
overview, 187
sources of, 189–90
sensitivity analysis for, 199–200
sensitivity of screening tests,
388, 390, 389
sensitivity analysis to estimate effects of
bias, 199
sentinel surveillance, 327–9
severe acute respiratory syndrome (SARS) epidemic (2003)
case–fatality rate, 58–9
global response to, 59–60
identification of, 76, 78
management of media, 347
sexual activity and myocardial infarction (MI, heart attack), 126
significance
statistical, 169, 171
statistical versus clinical (or practical), 181–2
Simpson’s paradox, 217, 223
SIR see standardised incidence ratio
smallpox, 23
eradication (1980), 316
smoking
and CHD, 155–6
and lung cancer, 16, 23, 95, 142, 218–19, 266
and oesophageal cancer, 253
and ovarian cancer, 195
and Parkinson’s disease, 118
and response rates, 190
and stroke, 97, 115, 140–2, 148, 150–1
British Doctors’ Study, 16, 23–4, 41, 117, 155, 281–2
SMR see standardised mortality ratio
Snow, John (1813–1858) and cholera, 13, 14, 15, 275
social epidemiology, 106
specificity
as factor in evaluating causality, 276
of screening tests, 387, 394
standard populations, 54, 451–3
standardisation
direct, 57, 451
indirect, 56–7, 457
standardised rates, 49, 53
standardised incidence ratio (SIR), 52–3, 56–7, 147
standardised mortality ratio (SMR), 52–3, 56–7, 96, 458
statistical significance, 169, 171, 177, 182, 260
stillbirth or fetal death rate, 61, 62
stillbirth or fetal death ratio, 61, 62
stomach cancer and *Helicobacter pylori* infection, 97, 250, 285–6
stratification
to control confounding, 241–2
to identify confounding, 241–2
strength of association, in evaluating causation, 176, 280
streptokinase and heart attack mortality, 109
stroke and smoking, 97, 115, 140–2, 148, 150–1
study designs
case–cohort, 120
case–control, 121–5
case–crossover, 125–6
cohort, 114–18
cross-sectional, 127–8
ecological (correlation), 129–30
intervention (experimental), 24, 108–9
migrant, 96
nested case–control, 121
pre–post intervention, 113
study size
and confounding, 231, 257
and *p*-values, 179
and power, 175–6
subject selection error see selection bias
sudden infant death syndrome (SIDS), study of
risk factors, 123
sufficient cause, 271
suicide
prevention programme (US Air Force), 374
rates, 70, 374–5
years of potential life lost, 70
surveillance, 82, 87, 100, 265, 315–16, 318
active, 320, 327
definition, 318–19
digital, 325–7
evaluation of surveillance systems, 321
event-based, 324–5
for drug safety, 119
for polio, 319
for risk factors, 328
indicator-based, 322–4
mass-gathering, 327
notifiable diseases, 323, 325, 329
passive surveillance, 320
scope of, 314–15
sentinel surveillance, 327–8
syndromic, 319–20
rumour surveillance, 325
survival rate and relative survival rate, 59
systematic reviews, 289
assessing heterogeneity, 297
assessing the quality of, 303–4
assessment of causality, 306
graphical display of results, 294
identifying the literature, 291
inclusion criteria, 292
meta-analysis, 297, 299
pooled analysis, 299
for public health policy, 316
publication bias, 291
study designs and quality of evidence, 302
summarising the data, 294

TB see tuberculosis
temporality, as factor in evaluating causality, 276
tertiary prevention, 356
Thai Health Risk Transition Study, 423
thalidomide and birth defects, 307
Titanic sinking, death rates, 10
transmission of infectious disease
airborne, 342
and control strategies, 356
direct, 341
horizontal, 341
indirect, 341
vectors, 341
vehicle, 341
vertical, 341
tuberculosis
BCG vaccination, 357–8
factors in mortality reduction, 358–9
US Physicians’ Health Study, 108
USA, trends in mortality rates, 55
US Preventive Services Task Force (USPSTF), 288, 294, 303, 305, 309
vaccination
BCG (tuberculosis) vaccination, 357–8
benefits and concerns, 265
measles, mumps and rubella (MMR) vaccination strategy, 337
vaginal cancer risk, and diethylstilboestrol (DES) exposure, 176
validation studies, 211, 213, 256
validity
external (generalisability), 188, 262–3
internal, 188–9, 214
verbal autopsy, 82
veteran health and mortality rates, 193
virulence, 339
vital statistics, 77–81
vitamin A and childhood mortality, 109
volunteer bias, 189–90, 402–3

water fluoridation and dental health, 113
World Cancer Research Fund (WCRF), 288, 307
World Health Organization (WHO), 2, 54, 68, 94, 314, 371
Global Health Observatory, 94
World Health Report, 70
writing papers, 264

years of potential life lost see potential years of life lost, expected years of life lost
zoonoses, 337, 341